Asunto(s)
Infecciones por Helicobacter , Helicobacter pylori , Síndrome Metabólico , Inhibidor 1 de Activador Plasminogénico , Factor de von Willebrand , Humanos , Infecciones por Helicobacter/complicaciones , Factor de von Willebrand/metabolismo , Inhibidor 1 de Activador Plasminogénico/sangre , Hepatopatías , Enfermedad CrónicaRESUMEN
In this Editorial, we highlight the possible role that metabolism dysfunction-associated steatotic liver disease (MASLD) may play in the future, regarding liver disease in patients with transfusion-dependent ß-thalassemia (TDBT). MASLD is characterized by excessive accumulation of fat in the liver (hepatic steatosis), in the presence of cardiometabolic factors. There is a strong correlation between the occurrence of MASLD and insulin resistance, while its increased prevalence parallels the global epidemic of diabetes mellitus (DM) and obesity. Patients with TDBT need regular transfusions for life to ensure their survival. Through these transfusions, a large amount of iron is accumulated, which causes saturation of transferrin and leads to the circulation of free iron molecules, which cause damage to vital organs (primarily the liver and myocardium). Over the past, the main mechanisms for the development of liver disease in these patients have been the toxic effect of iron on the liver and chronic hepatitis C, for which modern and effective treatments have been found, resulting in successful treatment. Additional advances in the treatment and monitoring of these patients have led to a reduction in deaths, and an increase in their life expectancy. This increased survival makes them vulnerable to the onset of diseases, which until recently were mainly related to the non-thalassemic general population, such as obesity and DM. There is insufficient data in the literature regarding the prevalence of MASLD in this population or on the risk factors for its occurrence. However, it was recently shown by a study of 45 heavily transfused patients with beta-thalassemia (Padeniya et al, BJH), that the presence of steatosis is a factor influencing the value of liver elastography and thus liver fibrosis. These findings suggest that future research in the field of liver disease in patients with TDBT should be focused on the occurrence, the risk factors, and the effect of MASLD on these patients.
RESUMEN
Introduction: Human leukocyte antigen (HLA) polymorphisms have been associated with the development of various autoimmune diseases, as well as malignant neoplasms. Non-Hodgkin lymphomas (NHLs) are a heterogenous group of lymphoid malignancies in which a genetic substrate has been established and is deemed to play a crucial role in disease pathogenesis. This study aimed to identify whether variations in the HLA gene region were associated with diffuse large B-cell lymphoma (DLBCL) risk and prognosis. Methods: We defined HLA class I (HLA-A, HLA-B, HLA-C) and class II (HLA-DRB1, HLA-DQB1) alleles in 60 patients with DLBCL and compared the results to those found by 236 healthy adult donors from the bone marrow bank of Northern Greece. HLA typing was performed by two molecular methods, Sequence - Specific Oligonucleotide HLA typing (SSO) and Sequence - Specific Primer HLA typing (SSP), from white blood cells recovered from peripheral blood. The phenotypic frequencies of HLA-A, HLA-B, HLA-C, HLA-DRB1 and HLA-DQB1 between patients and controls were compared with the 2-sided Fisher's exact test. Results with p-value <0.05 were considered statistically significant. Odds Ratios with 95% Confidence Intervals were calculated to further strengthen the results. The 2-sided Fisher's exact test was also applied to alleles found only in one of the two groups, while the odds ratios together with the confidence intervals were corrected with Haldane-Anscombe method. Results: Among the studied HLA polymorphisms, the frequency HLA-C*12 allele was significantly lower in patients with DLBCL compared with control subjects (6.7% vs. 34.7%, OR = 0.16, 95% CI: 0.04-0.44). Frequency of HLA-B*39 was significantly lower in patients with DLBCL compared with controls, but due to the low frequency of this polymorphism in the studied population and small sample size, determinations regarding the significance of this findings were limited. Survival analysis revealed that the presence of HLA-C*12 was not associated with improved or worsened overall and progression-free survival. No statistically significant associations were observed in the phenotypic frequencies of HLA-A, HLA-DQB1, HLA-DRB1 and the rest of HLA-B alleles between the control and DLBCL groups. Discussion: Collectively, our results provide valuable insight regarding the role of HLA variations on DLBCL risk. Further studies are required to consolidate our findings and ascertain the clinical implications of these genetic variations on DLBCL management and prognosis.
RESUMEN
Gestational diabetes mellitus (GDM) is a common metabolic disorder that often develops during pregnancy, characterized by glucose intolerance and insulin resistance (IR). To ensure the well-being of both the mother and the fetus, the body undergoes multiple metabolic and immunological changes that result in peripheral IR and, under certain hereditary or acquired abnormalities, GDM in predisposed women. The adverse short- and long-term effects of GDM impact both the mother and the fetus. Nutrition seems to play an important role to prevent GDM or improve its evolution. An emphasis has been given to the proportion of carbohydrates (CHO) relative to protein and lipids, as well as dietary patterns, in GDM. The effects of CHO on postprandial glucose concentrations are reflected in the glycemic index (GI) and glycemic load (GL). Diets rich in GI and GL may induce or exacerbate IR, whereas diets low in GI and GL appear to enhance insulin sensitivity and improve glycemic control. These positive outcomes may be attributed to direct interactions with insulin and glucose homeostasis or indirect effects through improved body composition and weight management. This comprehensive narrative review aims to explore the significance of nutrition, with a focus on the critical evaluation of GI and GL in the dietary management of women with GDM.
Asunto(s)
Diabetes Gestacional , Carga Glucémica , Resistencia a la Insulina , Embarazo , Femenino , Humanos , Diabetes Gestacional/prevención & control , Índice Glucémico , Dieta , Insulina , Glucosa , Glucemia/metabolismo , Carbohidratos de la DietaRESUMEN
Beta thalassemia is the most common genetic blood disorder, characterized by reduced production or complete absence of beta-globin chains. The combination of systematic red blood cell transfusion and iron chelation therapy is the most readily available supportive treatment and one that has considerably prolonged the survival of thalassemia patients. Despite this, the development of endocrine abnormalities correlated with beta thalassemia still exists and is mostly associated with iron overload, chronic anemia, and hypoxia. A multifactorial approach has been employed to investigate other factors involved in the pathogenesis of endocrinopathies, including genotype, liver disease, HCV, splenectomy, socioeconomic factors, chelation therapy, and deficiency of elements. The development of specific biomarkers for predicting endocrinopathy risk has been the subject of extensive discussion. The objective of the present narrative review is to present recent data on endocrinopathies in beta thalassemia patients, including the prevalence, the proposed pathogenetic mechanisms, the risk factors, the diagnostic methods applied, and finally the recommended treatment options.
Asunto(s)
Enfermedades del Sistema Endocrino , Talasemia beta , Humanos , Talasemia beta/terapia , Talasemia beta/complicaciones , Talasemia beta/epidemiología , Talasemia beta/diagnóstico , Enfermedades del Sistema Endocrino/etiología , Enfermedades del Sistema Endocrino/terapia , Enfermedades del Sistema Endocrino/diagnóstico , Sobrecarga de Hierro/terapia , Quelantes del Hierro/uso terapéuticoRESUMEN
Healthcare systems around the globe are still facing the evolving threat of the coronavavirus-19 (COVID-19) pandemic. Hemoglobinopathies include a group of genetic disorders, with the two main entities being thalassemias and sickle cell disease. Due to their immunocompromised status, such patients have been protected as extremely vulnerable to COVID-19 infection. We studied patients with different hemoglobinopathies, consecutively monitored at our center, who were infected with severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) during the second and third waves of the pandemic in Greece (September 2020-April 2021), and associated the outcomes of the infection with the following factors: age, employment, blood type, liver and heart hemosiderosis, splenectomy, concomitant endocrine disorders and transfusion dependency. Among 250 patients monitored at our center, 14 were infected with COVID-19. Nine of them were hospitalized but no one required intensive care unit support and all of them responded to the generally applied treatment plan, despite their comorbidities. Notwithstanding the slightly increased prevalence of COVID-19 in patients with hemoglobinopathies compared to the general population, self-applied measures are still thought to be effective, as our patients got infected through their already sick family members.
Asunto(s)
COVID-19 , Hemoglobinopatías , Talasemia , COVID-19/epidemiología , Grecia/epidemiología , Hemoglobinopatías/epidemiología , Humanos , SARS-CoV-2 , Talasemia/epidemiología , Talasemia/terapiaRESUMEN
Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are essential weapons to control the spread of the coronavirus disease-19 (COVID-19) pandemic and protect immunocompromised patients. With a greater susceptibility to infection, sickle cell disease (SCD) patients are considered as "high risk" patients during the current COVID-19 pandemic. In our study, we try to determine the immune response of adult SCD patients monitored at our center after the first and second dose of the qualified mRNA vaccines available and correlate them to several disease-specific markers, as well as complement activation. The results demonstrate that the levels of neutralizing antibodies (nAbs) against SARS-CoV-2 were adequate for most patients studied after the second dose and there seemed to be a certain association with complement activation. Further studies are critical to determine the durability of this immune response and the potential benefit of a third dose.
RESUMEN
The potential clinical applications of the powerful in vitro-transcribed (IVT)-mRNAs, to restore defective protein functions, strongly depend on their successful intracellular delivery and transient translation through the development of safe and efficient delivery platforms. In this study, an innovative (international patent-pending) methodology was developed, combining the IVT-mRNAs with the protein transduction domain (PTD) technology, as an efficient delivery platform. Based on the PTD technology, which enables the intracellular delivery of various cargoes intracellularly, successful conjugation of a PTD to the IVT-mRNAs was achieved and evaluated by band-shift assay and NMR spectroscopy. In addition, the PTD-IVT-mRNAs were applied and evaluated in two protein-disease models, including the mitochondrial disorder fatal infantile cardioencephalomyopathy and cytochrome c oxidase (COX) deficiency (attributed to SCO2 gene mutations) and ß-thalassemia. The PTD-IVT-mRNA of SCO2 was successfully transduced and translated to the corresponding Sco2 protein inside the primary fibroblasts of a SCO2/COX-deficient patient, whereas the PTD-IVT-mRNA of ß-globin was transduced and translated in bone marrow cells, derived from three ß-thalassemic patients. The transducibility and the structural stability of the PDT-IVT-mRNAs, in both cases, were confirmed at the RNA and protein levels. We propose that our novel delivery platform could be clinically applicable as a protein therapy for metabolic/genetic disorders.
RESUMEN
Aim: ß-Type hemoglobinopathies are characterized by vast phenotypic diversity as far as disease severity is concerned, while differences have also been observed in hydroxyurea (HU) treatment efficacy. These differences are partly attributed to the residual expression of fetal hemoglobin (HbF) in adulthood. The Krüppel-like family of transcription factors (KLFs) are a set of zinc finger DNA-binding proteins which play a major role in HbF regulation. Here, we explored the possible association of variants in KLF gene family members with response to HU treatment efficacy and disease severity in ß-hemoglobinopathies patients. Materials & methods: Six tag single nucleotide polymorphisms, located in four KLF genes, namely KLF3, KLF4, KLF9 and KLF10, were analyzed in 110 ß-thalassemia major patients (TDT), 18 nontransfusion dependent ß-thalassemia patients (NTDT), 82 sickle cell disease/ß-thalassemia compound heterozygous patients and 85 healthy individuals as controls. Results: Our findings show that a KLF4 genomic variant (rs2236599) is associated with HU treatment efficacy in sickle cell disease/ß-thalassemia compound heterozygous patients and two KLF10 genomic variants (rs980112, rs3191333) are associated with persistent HbF levels in NTDT patients. Conclusion: Our findings provide evidence that genomic variants located in KLF10 gene may be considered as potential prognostic biomarkers of ß-thalassemia clinical severity and an additional variant in KLF4 gene as a pharmacogenomic biomarker, predicting response to HU treatment.
Asunto(s)
Anemia de Células Falciformes/tratamiento farmacológico , Factores de Transcripción de la Respuesta de Crecimiento Precoz/genética , Hemoglobinopatías/tratamiento farmacológico , Factores de Transcripción de Tipo Kruppel/genética , Talasemia beta/tratamiento farmacológico , Anemia de Células Falciformes/sangre , Anemia de Células Falciformes/epidemiología , Anemia de Células Falciformes/genética , Biomarcadores Farmacológicos/metabolismo , Femenino , Hemoglobina Fetal/genética , Estudios de Asociación Genética , Hemoglobinopatías/sangre , Hemoglobinopatías/epidemiología , Hemoglobinopatías/genética , Humanos , Hidroxiurea/administración & dosificación , Hidroxiurea/efectos adversos , Factor 4 Similar a Kruppel , Masculino , Polimorfismo de Nucleótido Simple/genética , Índice de Severidad de la Enfermedad , Resultado del Tratamiento , Talasemia beta/sangre , Talasemia beta/epidemiología , Talasemia beta/genéticaRESUMEN
Treatment of ß-thalassemia major (ß-TM) includes regular blood transfusions and iron chelation with subcutaneous injection of deferoxamine (DFO). During the last decade, a new chelation agent, deferiprone (L1), was introduced. The purpose of our study was to determine the level of awareness/education regarding chelation therapy, the degree of compliance to this therapy and their views of L1 in patients with ß-TM. A relevant questionnaire was administered to 36 patients (12-26 years old) who were on combination chelation therapy with both DFO and L1. The majority of patients was well aware/educated about chelation therapy (76.6%), was compliant with this therapy (74.4%) and had a positive view towards oral chelation (86.0%). In conclusion, most patients with ß-TM who were on combination chelation therapy with DFO and L1 were satisfied with this treatment and this results in high compliance rates.
Asunto(s)
Terapia por Quelación/métodos , Deferoxamina/uso terapéutico , Piridonas/uso terapéutico , Talasemia beta/tratamiento farmacológico , Adolescente , Adulto , Distribución de Chi-Cuadrado , Niño , Deferiprona , Quimioterapia Combinada , Conocimientos, Actitudes y Práctica en Salud , Humanos , Quelantes del Hierro/uso terapéutico , Cooperación del Paciente/estadística & datos numéricos , Opinión Pública , Encuestas y Cuestionarios , Adulto JovenRESUMEN
BACKGROUND: Pulmonary dysfunction represents one of the most undervalued and less recognized complications in patients with ß-thalassaemia. OBJECTIVES: The aim of this study was to assess the pattern of pulmonary dysfunction and consequently to investigate possible associated factors that might contribute to lung impairment in young patients with ß-thalassaemia major. METHODS: Fifty-two children and young adults (mean age: 21.33 ± 6.24 years) with ß-thalassaemia major on conventional treatment (transfusions and iron chelation therapy) were included in the study. A complete computerized pulmonary function testing (PFT) system for recording pulmonary diffusion capacity and simultaneous determination of alveolar volume and pulmonary volumes was equipped. RESULTS: Results showed that 20 patients (38.46%) had restrictive pulmonary pattern that was preferentially observed in older and shorter patients. Serum ferritin levels were higher in the restrictive group (2,096 ± 1,831 ng/dl) compared to patients with normal pulmonary function (1,354 ± 942 ng/dl) (P = 0.066). Diffusional impairment characterized by significantly lower DLCO*% values, was observed in the restrictive group (P = 0.004), implicating the 62.5% of the population studied. Paired linear correlations showed that age was negatively correlated to DLCO*% (r = -0.548, P < 0.001) and SaO(2) % (r = -0.789, P < 0.001) and with most of the pulmonary functional parameters that determine a restrictive. Multivariate regression analysis identified age as the major predictor for restrictive pulmonopathy followed by serum ferritin levels. CONCLUSIONS: Our study shows that pulmonary impairment is shown in a great proportion even among asymptomatic young thalassaemic patients, thus, regular screening of pulmonary function should be adopted in the routine clinical follow up of these patients.
Asunto(s)
Enfermedades Pulmonares/fisiopatología , Talasemia beta/fisiopatología , Adolescente , Adulto , Factores de Edad , Niño , Femenino , Ferritinas/sangre , Humanos , Enfermedades Pulmonares/etiología , Masculino , Pruebas de Función Respiratoria , Factores de Riesgo , Talasemia beta/complicacionesAsunto(s)
Antivirales/efectos adversos , Hepatitis C Crónica/tratamiento farmacológico , Interferón-alfa/efectos adversos , Polietilenglicoles/química , Ribavirina/efectos adversos , Talasemia beta/inducido químicamente , Adulto , Antivirales/administración & dosificación , Antivirales/química , Antivirales/uso terapéutico , Terapia por Quelación , Quimioterapia Combinada/efectos adversos , Femenino , Grecia , Hepatitis C Crónica/complicaciones , Homocigoto , Humanos , Interferón alfa-2 , Interferón-alfa/administración & dosificación , Interferón-alfa/química , Interferón-alfa/uso terapéutico , Quelantes del Hierro/uso terapéutico , Sobrecarga de Hierro/complicaciones , Sobrecarga de Hierro/prevención & control , Masculino , Persona de Mediana Edad , Proteínas Recombinantes/administración & dosificación , Proteínas Recombinantes/efectos adversos , Proteínas Recombinantes/química , Proteínas Recombinantes/uso terapéutico , Ribavirina/administración & dosificación , Ribavirina/química , Ribavirina/uso terapéutico , Reacción a la Transfusión , Resultado del Tratamiento , Talasemia beta/complicaciones , Talasemia beta/genética , Talasemia beta/terapiaRESUMEN
We herein report a case of a thalassemic-patient who was on deferasirox chelation therapy and admitted to the emergency department because of fever, diffuse abdominal pain and altered mental status. Despite the appropriate treatment he died two days later due to cardiac arrest. As we failed to recognize any etiology and the patients' relatives denied a post mortem examination due to religious reasons, we cannot provide any additional data. However, we are wondering whether this incident might be related to deferasirox.
Asunto(s)
Benzoatos/efectos adversos , Terapia por Quelación/efectos adversos , Quelantes del Hierro/efectos adversos , Insuficiencia Multiorgánica/inducido químicamente , Triazoles/efectos adversos , Talasemia beta/tratamiento farmacológico , Adulto , Deferasirox , Resultado Fatal , Humanos , Masculino , Factores de RiesgoAsunto(s)
Sobrecarga de Hierro/diagnóstico , Cirrosis Hepática/diagnóstico por imagen , Adulto , Estudios de Cohortes , Diagnóstico por Imagen de Elasticidad/métodos , Femenino , Hepatitis C Crónica/complicaciones , Humanos , Imagen por Resonancia Magnética , Masculino , Adulto Joven , Talasemia beta/complicacionesRESUMEN
OBJECTIVES: Despite advances in conventional treatment, iron-induced cardiomyopathy is still the most frequent cause of death among patients with beta-thalassaemia major. Recent studies have correlated increased myocardial iron content to decreased levels of vitamin D in thalassaemic patients. The aim of this study was to measure parathormone (PTH) and metabolites of vitamin D and consequently to investigate whether these parameters predispose to myocardial iron overload in patients with beta-thalassaemia major. METHODS: In 62 patients (29 M and 33 F, mean age: 22.79 +/- 6.18 yr) with beta-thalassaemia major levels of intact parathormone (iPTH) and vitamin D metabolites [25(OmicronH)D(3) and 1,25(OmicronH)(2)D(3)] were measured in serum. Additionally, estimation of myocardial iron content was performed by magnetic resonance imaging, whereas mean serum ferritin concentrations were calculated for 1 yr prior to the study. RESULTS: Results showed markedly decreased levels of serum 25(OH)D(3) in 37 patients (60%), whereas 7 patients (11%) had borderline 25(OH)D(3) levels (between 50 and 75 nmol/L). Serum iPTH levels were significantly higher in patients having increased myocardial iron compared to those having normal myocardial iron (44.04 +/- 22.09 pg/mL vs. 31.39 +/- 14.30 pg/mL, P = 0.017). Multivariant regression analysis identified PTH levels as the major predictor of increased myocardial iron.
Asunto(s)
Sobrecarga de Hierro/etiología , Hierro/análisis , Miocardio/química , Hormona Paratiroidea/sangre , Reacción a la Transfusión , Deficiencia de Vitamina D/etiología , Talasemia beta/terapia , Adolescente , Adulto , Calcifediol/sangre , Calcitriol/sangre , Niño , Femenino , Ferritinas/sangre , Humanos , Hierro/sangre , Sobrecarga de Hierro/patología , Imagen por Resonancia Magnética , Masculino , Miocardio/patología , Deficiencia de Vitamina D/sangre , Adulto Joven , Talasemia beta/sangre , Talasemia beta/patologíaRESUMEN
Our aim was to assess liver iron content, in thalassaemic patients, by using three different MR protocols and compare their data. Ninety-four thalassaemic patients (44 M and 50 F, mean age 25.82 +/- 8.3 yrs), were enrolled in the study. In each patient, three measurements of the liver iron content were performed, with the use of a single imager, equipped with a 1.5 Tesla magnet. Liver R2* was measured on gradient-echo sequence. Calculation of MR-HIC values was based on an algorithm using liver to muscle (L/M) ratios in five axial gradient-echo sequences. Finally, determination of liver R2 employed a 16-echo, spin-echo pulse sequence. Additionally, myocardial R2* value was determined for each patient. Results showed that all three magnetic resonance imaging (MRI) methods were highly correlated to each other and significantly correlated to serum ferritin concentrations. Liver R2 method showed an increased sensitivity in detecting liver iron contents in the upper range. No correlation occurred between each liver MRI parameter and myocardial R2* values. Finally, we managed to provide formulae for equating values obtaining with any of these three MRI methods.
Asunto(s)
Hierro/análisis , Hígado/química , Imagen por Resonancia Magnética/métodos , Talasemia/metabolismo , Adolescente , Adulto , Algoritmos , Femenino , Humanos , Imagen por Resonancia Magnética/normas , Masculino , Miocardio/metabolismo , Adulto JovenRESUMEN
Oncocytomas are a rare group of neoplasms of the parotid gland which have been correlated to various viral infections. We report the first case of a patient with parotid oncocytoma and a previous history of chronic HBV infection.
RESUMEN
OBJECTIVES: Osteopenia/osteoporosis is a major component of morbidity even in young patients with beta-thalassaemia major. Dual energy X-ray absorptiometry (DXA) is the reference method for determining bone mineral density (BMD). Quantitative ultrasound sonography (QUS) for bone measurement is a relatively new, inexpensive and radiation-free method that could serve as an alternative to DXA. Our aim was to assess bone status in thalassaemic patients both with QUS and DXA and, consequently, to investigate the degree of correlation between the two methods. METHODS: Thirty-three patients (15 male and 18 female) with beta-thalassaemia major, regularly transfused and systematically iron-chelated, participated in the study. Mean age was 22.0 +/- 8.0 yr (range: 6.5-41.0 yr). All patients were evaluated with QUS at radius and tibia and had DXA scan at lumbar spine vertebrae (L2-L4), whereas 20 patients were additionally assessed with DXA at the left hip (femoral neck, trochanter region and Ward's triangle). RESULTS: Results were expressed as Z-scores compared with sex- and age-matched population. Lowest mean Z-scores measured with DXA were recorded at lumbar spine and Ward's triangle (-1.1 +/- 1.13 and -0.95 +/- 1.07, respectively). Lowest mean QUS-derived Z-scores were measured at radius, statistically significant compared with Z-scores measured at tibia (-0.6 +/- 1.1 vs. 0.4 +/- 1.1, P < 0.001). QUS measurements at radius were significantly correlated to QUS measurements at tibia (r = 0.51, P = 0.002). The latter were correlated to BMD measured at lumbar spine (r = 0.516, P = 0.002) and at trochanter region (r = 0.646, P = 0.003). All BMD measurements at hip were significantly correlated to each other. Lumbar spine BMD was correlated to BMD at femoral neck (r = 0.607, P = 0.003) and to BMD at Ward's triangle (r = 0.438, P = 0.027). Finally, no agreement was recorded between the two methods in identifying thalassaemic patients at risk for osteoporosis (kappa = 0.203, P = 0.04). CONCLUSION: Quantitative ultrasound sonography could not serve as an alternate to DXA.